Περίληψη:
The aim of the study was to investigate the effects of treatment with
1-thyroxine on iron and ferritin concentrations, and the efficacy of
continued treatment with iron substitution and 1-thyroxine in patients
with subclinical. hypothyroidism and manifested sideropenic anemia.
Thirty-three premenopausal women with sub, hypothyroidism and manifested
sideropenic anemia were randomly allocated to one of the three study
groups (Gr) of 11 patients each, and were studied during a three month
period. Patients in Gr I were treated with 1-thyroxine-100 mug/ daily,
in Gr II with iron proteinsuccinylate corresponding to 80 mg Fe+++ twice
a day, and in Gr III with both medicaments. In Gr I, treatment with
I-thyroxine did increase significantly iron and ferritin from 35 +/- 2.3
to 46 +/- 4.5 mug/dl, p < 0.01; and from 7.7 +/- 0.4 to 12.2 +/- 0.6
ng/ml, p < 0.01, respectively. In Gr II, treatment with iron
proteinsuccinylate increased iron from 36.6 +/- 2.3 to 67.9 +/- 6.8
mug/dl (p < 0.001), and ferritin from 8 +/- 0.5 to 14.1 +/- 0.6 ng/ mi
(p < 0.001). In Gr III the combined treatment raised iron from 34.3 +/-
2.3 to 78 +/- 7 mug/dl (p < 0.0001), and ferritin from 8 +/- 0.5 to 16.3
+/- 1.5 ng/ml (p < 0.0001). T-4 increased solidly from 89.6 +/- 4.2 to
103.7 +/- 10.2 nmol/l (p < 0.01), T-3 increased comparatively from 1.4
+/- 0.1 to 1.7 +/- 0.1 nmol/l p < 0.01, while TSH fell from 5.5 +/- 0.4
to 1.2 +/- 0.1 mU/l, p < 0.0001. The combined treatment with iron
preparation and 1-thyroxine led to a marked improvement of clinical and
biochemical-endocrine findings in patients, indicating a synergistic
effect of both drugs at various levels, and it is hereby proposed in
patients suffering from manifested sideropenic anemia and subclinical
hypothyroidism. The liquid form of ferrum used in our study was well
tolerated and compatible with 1-thyroxine when it was taken at least 2-3
hours following 1-thyroxine medication.
Συγγραφείς:
Duntas, LH
Krassas, GE
Mantzou, E
Koutras, DA
